Eli Lilly's acquisition of psychedelic drug maker AtaiBeckley extends Big Pharma's embrace of a stigmatized class of ...

Twelve years ago, Christian Angermayer took a mushroom trip that inspired him to try to create FDA-approved medicines from ...

Eli Lilly's acquisition of AtaiBeckley for up to $3.8 billion, marks a pivotal moment for psychedelic medicine.

Watch to see why companies are betting big on the therapeutic potential of a toad poison.

An in-depth look at the leading psychedelic stocks in the U.S. stock market this year. Here's what you need to know.

Lilly's purchase of AtaiBeckley is yet another strategic move in its bid to diversify its pipeline.

Doctors working in palliative care see promise in emerging therapies involving psychedelic drugs, but say many questions ...

Integration is more than journaling or reflection. It's the gradual process of living differently as insight becomes woven ...

As the psychedelic drug industry shifts from a speculative niche to a potential part of mainstream healthcare, investors have started to keep a careful eye on it.

July 16 (Reuters) - Eli Lilly will buy AtaiBeckley for up to $3.8 billion, the company said on Thursday, joining a race among ...